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Abstract

Impaired adherence to medication regimens is a serious concern for individuals
with schizophrenia linked to relapse and poorer outcomes. One possible reason for
poor adherence to medication is poor ability to remember future intentions, labeled
prospective memory skills. It has been demonstrated in several studies that
individuals with schizophrenia have impairments in prospective memory that are
linked to everyday life skills. However, there have been no studies, to our
knowledge, examining the relationship of prospective memory to medication
management skills, a key element of successful adherence. In this study 41
individuals with schizophrenia and 25 healthy adults were administered a
standardized test battery that included measures of prospective memory,
medication management skills, neurocognition and symptoms. Individuals with
schizophrenia demonstrated impairments in prospective memory (both time and
event-based) relative to healthy controls. Performance on the test of prospective
memory was correlated with the standardized measure of medication management
in individuals with schizophrenia. Moreover, the test of prospective memory
predicted skills in medication adherence even after measures of neurocognition
were accounted for. This suggests that prospective memory may play a key role in
medication management skills and thus should be a target of cognitive remediation
programs.
2

INTRODUCTION
Prospective memory (PM) is defined as the ability to remember a task and
perform it at an assigned time in the future (e.g., Shum et al., 2004). For example,
prospective memory is required to remember to attend a doctor’s appointment in the
future or to take medication at an assigned time. This process has been suggested to
involve four stages (Shum et al. 2004). The first is forming the intention to perform the
task, second is remembering this formed intention over a period of time; third is
continually remembering the time and method of executing the intention. Finally, one
must actually perform the intention and recall that it has been performed.
There has been increasing research interest in investigating PM impairments in
people with schizophrenia (Altgassen et al., 2008; Elvevag et al., 2003; Henry, et al.,
2007; Kondel, 2002; Kumar et al., 2005; Kumer et al., 2008; Ritch et al., 2003; Shum et
al., 2004; Twamley et al., 2007; Ungvari et al., 2008; Wang et al., 2007; Woods et al.,
2007). A number of studies have used computerized laboratory tasks modeled after that
of McDaniel and Einstein (2000) (e.g., Ungvari et al., 2008). These laboratory based
tasks all share important features including a delay between encoding and performance of
the intended action, an ongoing task carried out during the delay, and no explicit
reminder to perform the task when the cue appears. Tasks can be time-based (requiring
the individual to keep track of the time) or event-based (where an external cue indicates
that it is time to perform the intended action). Findings from these studies have
demonstrated consistent impairments in PM in individuals with schizophrenia compared
to a healthy adult sample in both time-based and event-based tasks. Although the
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impairments appear to be greater for time-based tasks in some studies (Shum et al., 2004;
Wang et al., 2009) others have not found a difference in performance on time-based tasks
compared to event-based tasks (Henry et al., 2007; Woods et al., 2007).
Consistent findings in schizophrenia include a relationship between PM and
retrospective memory and executive function, among others neurocognitive skills (Kumar
et al., 2008; Shum et al., 2004; Ungvari et al., 2008; Wang et al., 2008; Woods et al.,
2007), and severity of negative symptoms (Wang et al., 2009). Notably, performance on
PM tasks in schizophrenia, however, cannot be reduced to performance on tests of
traditional neurocognitive domains such as general cognitive skill, retrospective memory
and executive function (Henry et al., 2007). There has also been recent interest in the
relationship between PM performance and everyday tasks or activities of daily living
(ADL) (Ritch et al., 2003; Twamley et al. 2007; Ungvari et al., 2008; Zogg et al., 2010).
Ritch et al. (2003) reported that the sum score of time- and event-based PM tasks
predicted more than 29% of the variance of ADL scores. Twamley et al. (2006) reported
a positive relationship between a performance-based measure of ADLs (UPSA-Brief)
and the Memory for Intentions Screening Test (MIST). Event-based prospective memory
performance was the strongest predictor of everyday functioning. In contrast, Ungvari et
al. (2008) did not find a relationship between PM performance and ADLs using the
Functional Needs Assessment-Chinese Version. Discrepancies between studies may be
linked to differences in aspects of daily functioning assessed, such as cognitive difficulty
or automaticity: some everyday life tasks, such as appropriate grooming, would seem to
be less dependent upon prospective memory skills than others, such as remembering a
doctor’s appointment in the community at a specific time of day.
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One important daily activity that relies on PM is, of course, medication adherence.
Individuals with schizophrenia have been shown to perform poorly on performance-based
measures of medication management (Kurtz, et al., 2007). For example, Patterson and
colleagues used the Medication Management Ability Assessment (MMAA) to test the
medication management abilities of 104 older (over age 40) adults with schizophrenia
(Patterson et al., 2002). This test consists of a doctor-patient role-play in which the
subject is required to repeat a daily regime of medication. It was found that individuals
with schizophrenia made significantly more errors in the task than normal controls.
Construct validity for this task was supported by prescription refill records, relationship
to performance-based measures of everyday functioning and self-reported quality of life.
Those individuals that had more severe psychiatric symptoms performed worse than
those with less severe symptoms, and those individuals that were older performed worse
than those that were younger. Interestingly, performance on the MMAA correlated with
performance on an overall measure of cognitive function.
Using a cognitive screening measure Jeste et al. (2003) evaluated the relationship
between medication adherence and cognitive functioning in a sample of 104 outpatients
with schizophrenia or schizoaffective disorder. These authors reported that level of
cognitive functioning predicted ability to manage medications, with measures of
retrospective memory and conceptualization most closely linked to medication
management abilities.
Despite replicated findings that medication management skills are impaired in
schizophrenia, reflect (at least in part) deficits in cognition, and that prospective memory
would seem to be a fundamental skill necessary for medication management skills, to our
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knowledge, medication management skills has not been studied specifically in
relationship to PM performance, and other illness features in individuals with
schizophrenia.
In this study we used the MIST as an assessment of PM. The MIST is one of only
a few standardized clinical measures of PM (Raskin, Buckheit & Sherrod, 2011). The
MIST has the advantage of having been shown to have good psychometric properties
(Raskin, 2009; Woods et al., 2008), but to still allow for the analysis of various
underlying causes for the PM failure. Thus, the MIST allows for the comparison of long
and short delay times, event-based and time-based cues, and verbal and action responses
across balanced trials. We compared performance on the various aspects of the MIST to
a standardized measure of medication adherence, the MMAA, and performance on
measures of attention, working memory, and executive-function. First, we predicted that
prospective memory skills would be worse in individuals with schizophrenia compared to
demographically matched healthy adults and that time- and event-based prospective
memory would be equivalently impaired in individuals with schizophrenia relative to
demographically matched healthy adults. Second, in those with schizophrenia, we
predicted that prospective memory skills, measures of attention, learning and set-shifting
would be linked to medication management skills. Third, in those with schizophrenia we
predicted that prospective memory skills would explain variance in medication
management skills beyond that explained by traditional neuropsychological measures.
METHODS
Participants
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Forty-one individuals, (18 female), from the Schizophrenia Rehabilitation
Program (SRP) at the Institute of Living at Hartford Hospital in Hartford, CT (n=37) and
Intercommunity Mental Health Center in East Hartford, CT (n=4) participated. Twentyfive matched healthy adult individuals (12 female) were also tested.
Individuals with schizophrenia met criteria for schizophrenia or schizoaffective
diagnosis as described in the DSM-IV (American Psychiatric Society, 2000) via the
Structured Clinical Interview for the DSM-IV (SCID; First et al., 1995). Each patient also
met inclusion criteria of sufficient hearing and visual abilities, completion of a minimum
of eight years of schooling, and fluency in English. Exclusion criteria required that the
patient be free from any current alcohol or substance abuse, mental retardation as
evidenced by a history of services, or other neurologic or psychiatric illness, as well as
current treatment with electroconvulsive therapy. The Positive and Negative Syndrome
Scale (PANSS) scores were obtained to determine frequency and intensity of positive and
negative symptoms associated with schizophrenia at the time of the study (Kay, Fiszbein,
& Opler, 1987). Exclusion criteria for the healthy adults included auditory or visual
impairments, evidence of mental retardation, traumatic brain injury with a sustained loss
of consciousness, presence or history of any neurologic or psychiatric illness, lack of
proficiency in English or history of substance abuse or dependence. Demographic data
for individuals with schizophrenia and matched controls are presented in 1. There were
no significant differences between the groups in terms of age, gender or education. The
participants were compensated thirty dollars for their time.
Materials

7

The Medication Management Ability Assessment Manual (MMAA; Patterson et al.
2002):. This test involved a doctor-patient role play in which the patient was asked to
remember a regime of medication similar to one required in a typical day. Detailed
instructions were given to the participant explaining how to take the medication. The
dosage required, time of day and whether it required food was explained. The participant
was also shown the pill bottles that described the information that had just been explained.
After a delay of 45-60 minutes (during which other tests were administered) the
participants were asked to explain what time they would wake up, when they would eat
meals, and when they would go to sleep, explaining when they would take their
medications relative to these events throughout the day. Four mock medications were
included in this test; each represented with a different type of uncooked bean to simulate
different pills. The test was then scored based on the number of pills taken each time, the
number of times per day the pill was taken, and the total number of pills taken per day. A
total correct score was selected for analysis this this study.
Memory for Intentions Screening Test (MIST; Raskin, Buckheit, & Sherrod, 2011).
This was a prospective memory test that used both event-based and time-based cues to
assess the participant’s ability to remember tasks and carry them out. There were a total
of eight tasks which the participant was required to remember to perform at an assigned
time or when a specific cue was given. An example of an event-based cue was “when I
hand you an envelope, self-address it.” An example of a time cue was “in fifteen minutes,
please tell me to take a break.” The participant had access to a digital clock throughout
the test. While remembering to complete the tasks, participants worked on an ongoing
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task that was a word search puzzle. They were not permitted to write any information
down.
Finally, a battery of standardized neuropsychological measures was administered
chosen a priori to tap into underlying cognitive processes required for PM performance.
The tests used included measures of attention Trail Making Test A [TMT, Tombaugh,
2004]), learning and memory(California Verbal Learning Test-II-CVLT, Delis, Kramer,
Kaplan, & Ober, 2012]) and set-shifting (Trail Making Test B [TMT, Tombaugh, 2004]).
Procedure
Total testing lasted approximately one hour and fifteen minutes. All participants
gave written, informed consent and all procedures met institutional ethical approval.
When testing began, the first part of the MMAA was initially administered. During the
interim period, the MIST and the neuropsychological measures were administered
followed by the second, testing phase of the MMAA.
Data Analysis
None of the MIST measures were normally distributed as revealed by a series of
Shapiro-Wilk W tests (all ps<.01). Thus a series of non-parametric tests and Cohen’s d
(Hedges and Olkin, 1985) values were used to compare healthy control and patient
samples on variables from the MIST. In all cases reported ANOVA results on raw study
data were confirmed with rank-transformed data; in no case was there a discrepancy in
findings. Spearman rank-order correlations were calculated within the schizophrenia
group to assess the relationship of the MIST scores and other neurocognitive variables,
illness and demographic factors and medication management skills as measured by the
MMAA. Logistic regression using a cut-off of 80% accuracy or greater for intact
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medication management skills was selected in order to evaluate the relative contribution
of neurocognitive and the MIST summary score to MMAA scores in a logistic regression
analysis. Alpha was set at .05 and all analyses were two-tailed.
RESULTS
As can be seen in Table 2 individuals with schizophrenia performed significantly
more poorly than healthy adults on the MIST summary score (d=-.88), on responses to
time- (d=-.84) and event (d=-.67) based cues, and on 15-minute (d=-1.02) but not 2minute delayed responses, and on action (d=-1.09) but not verbal responses. Recognition
(d=-.54) performance and 24-hr (d=-.69) delay performance was impaired on the MIST
in the schizophrenia sample relative to healthy controls. There was no significant
difference in discrepancy between groups for the time and event-based cue responses
(p=.22) or action and verbal responses (p>.05). There was greater impairment on the long
as compared to short-delay items relative to healthy control performance (Group x Delay
interaction, [F(1, 64)=5.02, p=.021]). For error type, only the no response error type was
more common in individuals with schizophrenia (d=-.72). No response errors were
selectively more common in individuals with schizophrenia as compared to controls
relative to the other four error types as indicated by a group x error type interaction (F(4,
256)=5.09 p=.001).
Spearman rank-order correlations were conducted between clinical and
demographic variables, neurocognitive variables, MIST variables and the MMAA in the
schizophrenia sample (Table 3). CVLT-II T-scores (rho=.37), and Trails B time (rho=.30) and Summary scores (rho=.45) from the MIST were all related to MMAA scores.
With respect to subscales from the MIST, perfrormance on time (rho=.33*), and event
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cued (rho=.55**) responses, and responses that required an action (rho=.61**) rather
than a verbal statement were most closely linked to MMAA scores.
A forward stepwise logistic regression analysis was conducted to predict a
person’s ability to remember to take their medication using variables found to be
signficant in the correlational analysis: the summary score of prospective memory ability
from the MIST, the CVLT-II and Trails B. A binary variable was created for the MMAA
with a cutoff of 20 (80% accuracy). Neuropsychological variables were entered in block
one and summary score from the MIST was entered in block two. A test of the full model
against a constant only model was statistically significant, indicating that the predictors
as a set reliably distinguished between individuals having a total MMAA of less than 21
with those having a higher score (between 21 and 25) (chi square = 6.31, p =0.012 with
df =1). Prediction success overall was 73%. The Wald criterion demonstrated that Total
on the MIST made a significant contribution to prediction (p =.048). The remaining
tested variables were not significant predictors.
DISCUSSION
A growing body of research has documented deficits in prospective memory in
schizophrenia relative to demographically-matched, healthy adults. The current study was
designed to build on this work by both replicating previous findings in samples of healthy
adults and people with schizophrenia, and then investigating the relationship of impaired
prospective memory skills, commonly measured cognitive skills and symptoms to
performance-based medication adherence skills in individuals with schizophrenia. This
study is among the very first studies in the literature to investigate this relationship.
Consistent with our first hypothesis and a growing body of research (e.g., Woods et al.,
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2007; Elvevag et al., 2003), our results showed that prospective memory in schizophrenia
was impaired relative to demographically matched healthy adultperformance with effectsize impairment in the large range (d=.88 for the MIST summary score) which was
remarkably consistent with previous reports. Consistent with previous reports using an
identical index of prospective memory (Woods et al., 2007) there was no evidence that
responses to time-based prospective memory cues were more impaired than responses to
event-based cues. These findings provide more data that differences between
performance on time and event-based prospective tasks in previous studies (e.g., Shum et
al., 2004) may reflect the confounding of these conditions with the complexity of cueintention pairings which are carefully matched for difficulty across time and event-based
tasks on the MIST.
An analysis of error type revealed a selective deficit in no response (PM) errors as
compared to healthy controls, relative to the frequency other error types. These errors
reflect the participant giving no indication that there is an intention to be carried out.
These findings suggest that when prospective memory performance skills break down in
individuals with schizophrenia this most commonly reflects a failure to attend to or react
to the prospective memory cues on the MIST. However, our findings also indicate that
even when individuals with schizophrenia were able to detect a cue they more frequently
made incorrect responses as compared to healthy controls, suggesting evidence of either
poorly formed representations of cue-response pairings or problems with response
retrieval even when the cue was accurately recognized.
Analysis of our recognition results did not support the contention reported in two
previous studies with the MIST (Twamley et al., 2008; Woods et al., 2007) that
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adequately formed cue-intention relationships can be detected in individuals with
schizophrenia when strategic retrieval processes are minimized in the context of a
recognition test format, although differences in recognition effect-size results between
our study and previous studies were not large (d=.54 in the current study vs. d=.32 in the
Woods et al. study), and may reflect slight differences in recognition scoring procedures.
These findings coupled with our result that errors in response at a 15-minute delay
(d=1.02) were twice as large as those at a 2-minute delay (d=.50) suggest that prospective
memory skills may not conform to the common characteristics of retrospective memory
impairment in schizophrenia in which encoding and retrieval processes are impaired but
consolidation and maintenance processes remain largely intact (Aleman et al., 1999).
With respect to our second hypothesis, measures of set-shifting (Trails B), verbal
learning (CVLT-II) (but not visual attention [Trails A]) and prospective memory skills
were related to medication management skills (MMAA). These findings are consistent
with previous work investigating the relationship of summary cognitive screening
measures and medication management skills (e.g., Jeste et al. 2003) and extend these
findings to two key and specific cognitive function domains in schizophrenia. These
findings are also remarkably consistent with the reported relationship of prospective
memory skills to measures of ADL functional capacity in schizophrenia (Twamley et al.,
2008) and suggest similar magnitude relationships of prospective memory with the
specific skills of remembering to take a sequence of medications in the correct amount at
the correct times. The finding that errors for event cues were more closely related to
medication management skills than time-based cues was unanticipated as both strategic
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monitoring and self-initiated retrieval demands would seem greater for time-based cues
and thus would be more likely to be linked to medication management skills.
With respect to hypothesis three, results of binary logistic regression predicting
the adherence to a mock medication regimen, (defined as the likelihood of attaining 80%
accuracy on the medication management skill tests), showed that prospective memory
skills explained variance in adherence measures even after accounting for cognitive
measures supporting the potential incremental clinical utility of including prospective
memory measures for predicting medication management skills in schizophrenia.
Several limitations to the current study should be noted. First, study sample sizes
were modest and significant relationships may have been overlooked secondary to
limited power. Second, lack of adherence with prescribed medications involves a
complex interplay of cognitive and attitudinal factors including illness insight. The
medication management skill measure employed in the current study modeled cognitive
skills necessary for taking a complex regimen of medications, a necessary but not
sufficient skill for medication adherence. We note however that a paper published very
recently extends these findings to medication refill records (Lam et al., 2013). Third, the
neuropsychological test battery employed in the current study was limited in scope,
capturing only a few of the separable neurocognitive domains defined in factor analyses
using broad spectrum neurocognitive assessment batteries in schizophrenia.
In summary, the current results suggest that prospective memory is impaired in
schizophrenia relative to demographically matched controls, deficits are of equivalent
magnitude for time and event-based cues and this impairment is driven largely by failures
to recognize cues as well as errors in accurate retrieval of intention-cue pairings. In
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patients, both prospective memory measures and cognitive skills in set-shifting and
verbal learning predicted performance on a performance-based measure of medication
management skills. Importantly, prospective memory skills explained variance in
medication management skills beyond that of standardized neurocognitive measures.
These findings provide a rationale for the development of remediation strategies that
facilitate the encoding of cue-response relationships (perhaps with extended encoding
time or practice), and then provide environmental modifications that both increase the
salience of cues and tie these cues more directly to the target response as a means of
addressing the cognitive disabilities that interfere with medication adherence in
schizophrenia (e.g., Raskin & Sohlberg, 2011).
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Table 1: Demographic and disease information for individuals with schizophrenia and
healthy adults
HA (n = 24)
SCZ (n = 41)
Std.
Std.
Mean
Deviation
Mean
Deviation
t
Age
43.44
23.13
44.17
10.74
0.174 (NS)
Gender (% male)
52
56
Education(years)
13.92
2.23
12.37
2.54
-2.52 (NS)
Occupation*
7.2
0.58
7.10
0.81
-0.49 (NS)
Maximum Lifetime Duration of
Employment (months)
n/a
n/a
30.19
45.13
Lifetime Hospitalizations
n/a
n/a
3.78
2.84
Duration of Illness (years)
n/a
n/a
12.50
9.9
PANSS
Total Positive
n/a
n/a
15.05
5.57
Total Negative
n/a
n/a
17.35
6.99
Total General
n/a
n/a
34.59
9.89
Total PANSS
n/a
n/a
71.45
14.49
*Hollingshead (1977)
Note: HA = healthy adult; SCZ = schizophrenia; NS = not significant; n/a = not applicable;
PANSS = Positive and Negative Syndrome Scale
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Table 2: Prospective Memory and Medication Management Ability in the Study Samples
HA (n = 25)
Variable
MIST
Summary score (of 48)
Time (of 8)
Event (of 8)
2-min (of 8)
15-min (of 8)
Verbal (of 8)
Action (of 8)
Recognition (of 8)
24-hr (of 2)
Errors
NR
TS
LC
LT
PLO
MMAA
Total

SCZ (n = 41)

Mean

Std. Deviation

Mean

Std. Deviation

MannWhitney
U

ES (95% CI )

40.28
5.96
7.40
7.48
6.08
6.52
6.76
7.56
1.17

7.78
2.03
0.91
0.96
1.78
1.83
1.36
0.87
1.01

31.88
4.37
6.39
6.63
4.15
5.76
5.07
7.00
0.54

10.23
2.01
1.75
1.97
1.93
2.13
1.62
1.12
0.84

3.44**
2.97**
2.41*
1.74
3.69**
1.69
3.87**
2.24*
2.49**

-.88 (-1.40/-.36)
-0.84 (-1.36/-0.33)
-0.67 (-1.18/-0.16)
-0.50 (-1.01/0)
-1.02 ( -1.54/-.49)
-.37 (-.87/-.13)
-1.09 (-1.62/-.56)
-.54 (-1.09/-.03)
-.69 (-1.20/-.17)

0.65
0.32
0.44
0.24
0.00

1.04
0.48
0.58
0.44
0.00

2.02
0.71
0.54
0.34
0.02

2.21
0.95
0.71
0.57
0.16

3.02**
1.73
.36
0.56
0.78

-.72 (-1.24/-.22)
-.48 (-.9/.02)
-.15 (-.65/.35)
-.19 (-.69/.31)
-.16 (-.65/.34)

22.72

2.56

17.00

6.56

3.58**

-1.04 (-1.57/-.52)

Note: *p<.05; **p<.01; ***p<.001; HA = healthy adult; SCZ = schizophrenia; MIST = Memory for Intentions Screening Test;
MMAA = Medication Management Ability Assessment; NR = no response error; TS = task substitution error; LC = loss of content
error; LT = loss of time error; PLO = place losing error
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Table 3: Spearman correlations for individuals with
schizophrenia between neurocognitive, MIST and
MMMA variables (n=41)
MMAA Total
Demographic and Clinical Variables
Age
-0.26
Education
0.31
Duration of Illness
-0.08
Positive Symptoms
-0.23
Negative Symptoms
-0.18
MIST Variables
MIST Summary
0.45**
Time Cue
.33*
Event Cue
.55**
Verbal Response
.13
Action Response
.61**
2-minute Delay
.29
15-minute Delay
.44
Neuropsychological Measures
TMT-A
0.14
CVLT-II
0.37**
TMT-B
-0.30**

Note: *p<.05; **p<.01;; TMT= Trail Making Test;
CVLT = California Verbal Learning Test
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